(TMO) Thermo Fisher Scientific - Ratings and Ratios
Reagents, Instruments, Consumables, Diagnostics, Biopharma Services
TMO EPS (Earnings per Share)
TMO Revenue
Description: TMO Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is a leading provider of life sciences solutions, analytical instruments, and laboratory products, serving various markets including pharmaceutical, biotechnology, academic, and clinical laboratories. The companys diversified product portfolio and services cater to the growing demand for life sciences research, drug development, and diagnostics.
The companys business segments, including Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, demonstrate a strong presence in the industry. Notably, the Specialty Diagnostics segment offers a range of products, including immunodiagnostic reagent kits and transplant diagnostics, which are critical in clinical diagnosis and monitoring. Additionally, the Laboratory Products and Biopharma Services segment provides pharma services and clinical research, further expanding the companys offerings.
From a financial perspective, Thermo Fisher Scientific Inc. has demonstrated steady growth, with a market capitalization of over $162 billion. Key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating margin are crucial in evaluating the companys financial health. The companys return on equity (RoE) of 13.34% indicates a relatively stable return on shareholder investment. Furthermore, the forward P/E ratio of 19.08 suggests that the companys earnings are expected to grow, making it an attractive investment opportunity.
To further analyze the companys performance, other relevant KPIs could include the debt-to-equity ratio, interest coverage ratio, and cash flow conversion rate. These metrics would provide insights into the companys capital structure, ability to meet interest payments, and cash generation capabilities. Additionally, industry-specific KPIs, such as research and development (R&D) expenditure as a percentage of revenue, could be used to evaluate the companys commitment to innovation and staying ahead in the competitive life sciences industry.
TMO Stock Overview
| Market Cap in USD | 183,157m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1978-01-13 |
TMO Stock Ratings
| Growth Rating | -26.8% |
| Fundamental | 60.8% |
| Dividend Rating | 47.2% |
| Return 12m vs S&P 500 | -31.9% |
| Analyst Rating | 4.39 of 5 |
TMO Dividends
| Dividend Yield 12m | 0.41% |
| Yield on Cost 5y | 0.49% |
| Annual Growth 5y | 12.13% |
| Payout Consistency | 42.3% |
| Payout Ratio | 7.5% |
TMO Growth Ratios
| Growth Correlation 3m | 91.6% |
| Growth Correlation 12m | -83.9% |
| Growth Correlation 5y | 9.4% |
| CAGR 5y | 2.96% |
| CAGR/Max DD 5y | 0.07 |
| Sharpe Ratio 12m | -1.30 |
| Alpha | -31.08 |
| Beta | 0.576 |
| Volatility | 26.26% |
| Current Volume | 1407.7k |
| Average Volume 20d | 1992.3k |
| Stop Loss | 475 (-3%) |
| Signal | 0.94 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (6.58b TTM) > 0 and > 6% of Revenue (6% = 2.59b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -1.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 27.46% (prev 25.28%; Δ 2.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 7.58b > Net Income 6.58b (YES >=105%, WARN >=100%) |
| Net Debt (30.65b) to EBITDA (11.40b) ratio: 2.69 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (378.0m) change vs 12m ago -1.31% (target <= -2.0% for YES) |
| Gross Margin 39.58% (prev 39.78%; Δ -0.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.27% (prev 42.99%; Δ 0.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.63 (EBITDA TTM 11.40b / Interest Expense TTM 1.51b) >= 6 (WARN >= 3) |
Altman Z'' 4.25
| (A) 0.12 = (Total Current Assets 24.58b - Total Current Liabilities 12.72b) / Total Assets 101.23b |
| (B) 0.55 = Retained Earnings (Balance) 55.90b / Total Assets 101.23b |
| (C) 0.09 = EBIT TTM 8.53b / Avg Total Assets 99.86b |
| (D) 1.06 = Book Value of Equity 53.55b / Total Liabilities 50.63b |
| Total Rating: 4.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.84
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.89% = 1.44 |
| 3. FCF Margin 14.28% = 3.57 |
| 4. Debt/Equity 0.70 = 2.26 |
| 5. Debt/Ebitda 3.09 = -1.89 |
| 6. ROIC - WACC 2.25% = 2.81 |
| 7. RoE 13.27% = 1.11 |
| 8. Rev. Trend -15.01% = -0.75 |
| 9. Rev. CAGR 0.60% = 0.08 |
| 10. EPS Trend 50.34% = 1.26 |
| 11. EPS CAGR 4.55% = 0.46 |
What is the price of TMO shares?
Over the past week, the price has changed by +1.24%, over one month by +0.99%, over three months by +21.91% and over the past year by -19.87%.
Is Thermo Fisher Scientific a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TMO is around 432.02 USD . This means that TMO is currently overvalued and has a potential downside of -11.79%.
Is TMO a buy, sell or hold?
- Strong Buy: 18
- Buy: 7
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TMO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 550.3 | 12.4% |
| Analysts Target Price | 566.2 | 15.6% |
| ValueRay Target Price | 475.2 | -3% |
Last update: 2025-08-15 15:21
TMO Fundamental Data Overview
CCE Cash And Equivalents = 4.58b USD (last quarter)
P/E Trailing = 28.0857
P/E Forward = 21.5517
P/S = 4.2386
P/B = 3.6261
P/EG = 1.9769
Beta = 0.748
Revenue TTM = 43.21b USD
EBIT TTM = 8.53b USD
EBITDA TTM = 11.40b USD
Long Term Debt = 33.02b USD (from longTermDebt, last quarter)
Short Term Debt = 2.21b USD (from shortTermDebt, last quarter)
Debt = 35.23b USD (Calculated: Short Term 2.21b + Long Term 33.02b)
Net Debt = 30.65b USD (from netDebt column, last quarter)
Enterprise Value = 213.81b USD (183.16b + Debt 35.23b - CCE 4.58b)
Interest Coverage Ratio = 5.63 (Ebit TTM 8.53b / Interest Expense TTM 1.51b)
FCF Yield = 2.89% (FCF TTM 6.17b / Enterprise Value 213.81b)
FCF Margin = 14.28% (FCF TTM 6.17b / Revenue TTM 43.21b)
Net Margin = 15.24% (Net Income TTM 6.58b / Revenue TTM 43.21b)
Gross Margin = 39.58% ((Revenue TTM 43.21b - Cost of Revenue TTM 26.11b) / Revenue TTM)
Tobins Q-Ratio = 3.99 (Enterprise Value 213.81b / Book Value Of Equity 53.55b)
Interest Expense / Debt = 1.15% (Interest Expense 404.0m / Debt 35.23b)
Taxrate = 9.39% (from yearly Income Tax Expense: 657.0m / 7.00b)
NOPAT = 7.73b (EBIT 8.53b * (1 - 9.39%))
Current Ratio = 1.93 (Total Current Assets 24.58b / Total Current Liabilities 12.72b)
Debt / Equity = 0.70 (Debt 35.23b / last Quarter total Stockholder Equity 50.51b)
Debt / EBITDA = 3.09 (Net Debt 30.65b / EBITDA 11.40b)
Debt / FCF = 5.71 (Debt 35.23b / FCF TTM 6.17b)
Total Stockholder Equity = 49.62b (last 4 quarters mean)
RoA = 6.50% (Net Income 6.58b, Total Assets 101.23b )
RoE = 13.27% (Net Income TTM 6.58b / Total Stockholder Equity 49.62b)
RoCE = 10.32% (Ebit 8.53b / (Equity 49.62b + L.T.Debt 33.02b))
RoIC = 9.24% (NOPAT 7.73b / Invested Capital 83.62b)
WACC = 6.99% (E(183.16b)/V(218.39b) * Re(8.14%)) + (D(35.23b)/V(218.39b) * Rd(1.15%) * (1-Tc(0.09)))
Shares Correlation 5-Years: -100.0 | Cagr: -1.28%
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.95% ; FCFE base≈6.89b ; Y1≈6.88b ; Y5≈7.29b
Fair Price DCF = 335.8 (DCF Value 126.79b / Shares Outstanding 377.6m; 5y FCF grow -0.66% → 3.0% )
Revenue Correlation: -15.01 | Revenue CAGR: 0.60%
Rev Growth-of-Growth: 3.77
EPS Correlation: 50.34 | EPS CAGR: 4.55%
EPS Growth-of-Growth: -0.66
Additional Sources for TMO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle